This randomised, dose-finding study will evaluate the effects of a single medium or high dose of BPL-003 against a sub-perceptual dose in patients with Treatment Resistant Depression (TRD). TRD is defined as a failure to respond to two or more pharmacological treatments within the current depressive episode. It is taking place at approximately 40 sites across Australia, Germany, Poland, Spain, the United Kingdom and the United States.

This open-label Phase IIa study is taking place at Hammersmith Medicines Research in London and MAC Clinical Research in Liverpool and will assess the safety, tolerability, efficacy and pharmacokinetics of a two-dose administration of BPL-003 in patients with Treatment Resistant Depression (TRD) who are not taking SSRIs. TRD is defined as a failure to respond to two or more pharmacological treatments within the current depressive episode.

This open-label Phase IIa study is taking place at King’s College and Clerkenwell Health in London, and will investigate the safety and efficacy of a single dose of BPL-003 alongside an abstinence-oriented cognitive behavioural psychological intervention in patients with Alcohol Use Disorder. 

This open-label Phase IIa is taking place in Manchester and Liverpool and will assess the safety, tolerability, subjective effects and efficacy of a single dose of ELE-101 in patients with depression.

This open-label Phase IIa study is taking place at Hammersmith Medicines Research in London and will assess the safety, tolerability, efficacy and pharmacokinetics of BPL-003 co-administration in patients with Treatment Resistant Depression who are also taking citalopram, escitalopram, fluoxetine or sertraline.